|
Category: pharmaceuticals / chemical synthisis
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Appearance: | yellow-brown powder (est) |
| Assay: | 95.00 to 100.00 %
|
| Food Chemicals Codex Listed: | No |
| Melting Point: | 266.00 °C. @ 760.00 mm Hg
|
| Flash Point: | 32.00 °F. TCC ( 0.00 °C. ) (est)
|
| logP (o/w): | -0.653 (est) |
| Soluble in: |
| | water, 3.316 mg/L @ 25 °C (est) |
Organoleptic Properties:
| |
| Odor and/or flavor descriptions from others (if found). |
| |
| |
Cosmetic Information:
Suppliers:
Safety Information:
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
intraperitoneal-mouse LD50 18 mg/kg "CRC Handbook of Antibiotic Compounds," Vols.1- , Berdy, J., Boca Raton, FL, CRC Press, 1980Vol. 8(1), Pg. 195, 1982.
intravenous-mouse LD50 19400 ug/kg BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) Farmakologiya i Toksikologiya Vol. 29, Pg. 76, 1966.
intraperitoneal-rat LD50 18 mg/kg Indian Journal of Cancer. Vol. 5, Pg. 183, 1968.
intravenous-rat LD50 28700 ug/kg Toxicologist. Vol. 5, Pg. 176, 1985.
oral-rat LD50 1660 mg/kg Toxicologist. Vol. 5, Pg. 176, 1985.
|
| Dermal Toxicity: |
subcutaneous-cat LD50 120 mg/kg Arzneimittel-Forschung. Drug Research. Vol. 10, Pg. 135, 1960.
subcutaneous-dog LD50 70 mg/kg Arzneimittel-Forschung. Drug Research. Vol. 10, Pg. 135, 1960.
subcutaneous-frog LD50 70 mg/kg Arzneimittel-Forschung. Drug Research. Vol. 10, Pg. 135, 1960.
subcutaneous-mouse LD50 80 mg/kg Arzneimittel-Forschung. Drug Research. Vol. 10, Pg. 135, 1960.
subcutaneous-rabbit LD50 125 mg/kg Arzneimittel-Forschung. Drug Research. Vol. 10, Pg. 135, 1960.
|
| Inhalation Toxicity: |
inhalation-rat LC50 2200000 mg/m3 Toxicologist. Vol. 5, Pg. 176, 1985.
|
Safety in Use Information:
| Category: | pharmaceuticals / chemical synthisis |
| Recommendation for sanguinarine usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for sanguinarine flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
References:
Other Information:
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| (1,3)- | benzodioxolo(5,6-c)-1,3-dioxolo(4,5-i)phenanthridinium, 13-methyl- | | [1,3] | benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthridinium, 13-methyl- | | | dimethylenedioxy benzphenanthridine | | 13- | methyl-2H,10H-[1,3]dioxolo[4,5-i][1,3]dioxolo[4',5':4,5]benzo[1,2-c]phenanthridinium | | 13- | methyl[1,3]benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthridinium | | 13- | methyl[1,3]benzodioxolo[5,6-c][1,3]dioxolo[4,5-i]phenanthridin-13-ium | | | sanguinarin | | | sanguiritrin | | | sangvinarin | | | veadent | | | viadent |
Articles:
| PubMed: | Identification of sanguinarine metabolites in pig liver preparations by accurate mass measurements using electrospray ionization hybrid ion trap/time-of-flight mass spectrometry. |
| PubMed: | Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes. |
| PubMed: | Sanguinarine suppresses prostate tumor growth and inhibits survivin expression. |
| PubMed: | [Testing of the potentially probiotic lactobacilli for use in food supplements]. |
| PubMed: | Phenotype of hepatic xenobiotic metabolizing enzymes and CYP450 isoforms of sanguinarine treated rats: effect of P450 inducers on its toxicity. |
| PubMed: | Effect of argemone oil and argemone alkaloid, sanguinarine on Sertoli-germ cell coculture. |
| PubMed: | Investigation of sanguinarine and chelerythrine effects on CYP1A1 expression and activity in human hepatoma cells. |
| PubMed: | In vivo DNA damaging potential of sanguinarine alkaloid, isolated from argemone oil, using alkaline Comet assay in mice. |
| PubMed: | Quaternary benzo[c]phenathridine alkaloids sanguinarine and chelerythrine do not affect transcriptional activity of aryl hydrocarbon receptor: analyses in rat hepatoma cell line H4IIE.luc. |
| PubMed: | Effect of sanguinarine on the transport of essential nutrients in an everted gut sac model: role of Na+,K(+)-ATPase. |
| PubMed: | Sanguinarine and chelerythrine: assessment of safety on pigs in ninety days feeding experiment. |
| PubMed: | Outbreak of epidemic dropsy in Ethiopia: the clinical and therapeutic observation. |
| PubMed: | Identification of new inhibitors for human hematopoietic prostaglandin D2 synthase among FDA-approved drugs and other compounds. |
| PubMed: | Skin tumor promotion by argemone oil/alkaloid in mice: evidence for enhanced cell proliferation, ornithine decarboxylase, cyclooxygenase-2 and activation of MAPK/NF-kappaB pathway. |
| PubMed: | The plant alkaloid sanguinarine is a potential inhibitor of follicular angiogenesis. |
| PubMed: | Biometabolic elimination and organ retention profile of argemone alkaloid, sanguinarine, in rats and guinea pigs. |
| PubMed: | Laboratory investigation of epidemic dropsy in Addis Ababa, Ethiopia. |
| PubMed: | Outbreak investigation of epidemic dropsy in Addis Ababa, Ethiopia:. |
| PubMed: | Interaction of sanguinarine alkaloid, isolated from argemone oil, with hepatic cytochrome p450 in rats. |
| PubMed: | Removal of sanguinarine from edible oils contaminated with argemone oil. |
| PubMed: | Sanguinarine in the blood and urine of cases of epidemic dropsy. |
| PubMed: | Protective effect of topical application of α-tocopherol and/or N-acetyl cysteine on argemone oil/alkaloid-induced skin tumorigenesis in mice. |
| PubMed: | Epidemic dropsy: case report and the morphologic features in a patient who died at Tikur Anbessa Specialized Hospital. |
| PubMed: | Special issue on epidemic dropsy. |
| PubMed: | Integration of transcriptome, proteome and metabolism data reveals the alkaloids biosynthesis in Macleaya cordata and Macleaya microcarpa. |
| PubMed: | Food contamination. |
| PubMed: | Clinicoepidemiological, toxicological, and safety evaluation studies on argemone oil. |
| PubMed: | In vitro growth-inhibitory effect of plant-derived extracts and compounds against Paenibacillus larvae and their acute oral toxicity to adult honey bees. |
| PubMed: | Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. |
| PubMed: | Epidemic dropsy in India. |
| PubMed: | Natural feed additive of Macleaya cordata: safety assessment in rats a 90-day feeding experiment. |
| PubMed: | Epidemic dropsy in Andhra Pradesh due to contaminated ghee. |
| PubMed: | Epidemic dropsy in Trans Yamuma areas of Delhi and U.P. |
| PubMed: | Safety evaluation studies on argemone oil through dietary exposure for 90days in rats. |
| PubMed: | Epidemic dropsy in New Delhi. |
| PubMed: | Argemone oil poisoning. |
| PubMed: | Variability in the yield of benzophenanthridine alkaloids in wildcrafted vs cultivated bloodroot (Sanguinaria canadensis L.). |
| PubMed: | An out-break of epidemic dropsy in the Barabanki District of Uttar Pradesh, India: a limited trial for the scope of antioxidants in the management of symptoms. |
| PubMed: | Epidemic dropsy in the eastern region of Nepal. |
| PubMed: | Argemone oil induced cellular damage in the reproductive tissues of transgenic Drosophila melanogaster: protective role of 70 kDa heat shock protein. |
| PubMed: | The octadecanoic pathway: signal molecules for the regulation of secondary pathways. |
| PubMed: | Sodium retention from mouthwashes. |
| PubMed: | [Plaque and plaque control]. |
| PubMed: | Epidemic dropsy: observations on pathophysiology and clinical features during the Delhi epidemic of 1998. |
| PubMed: | Argemone mexicana and epidemic dropsy: phytopharmacology and putative sequelae and therapy. |
| PubMed: | Epidemic dropsy: atypical presentation. |
| PubMed: | The toxicity and pharmacokinetics of dihydrosanguinarine in rat: a pilot study. |
|